Review Article
Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
Table 2
Patient characteristics.
| | | Giaccone
et al., 2005 [35] | de Lavallade
et al., 2006 [37] | Vettenranta
et al., 1997 [34] | Huang
et al., 2005 [36] | Wang
et al., 2009 [39] | Wang
et al., 2011 [40] | Inagaki
et al., 2008 [38] | Inagaki
et al., 2014 [41] |
| | Number | | | | | | | | |
| | Age in years | 44 (27–66) | 51 (45–60) | 5.5 (3.6–11.6) | GIT32.5 (13–45) | 30 (8–50) | 28 (3–46) | 9 (2–16) | 7 (0–18) |
| | Gender (M/F) | 8/6 | NA | 2/3 | 29/13 | 53/33 | 21/13 | 12/15 | |
| Diagnosis
HM
Solid tumor
BH |
|
7
|
|
|
|
|
3
|
1
|
| Conditioning
Myeloablative
Nonmyeloablative |
2
|
4
|
|
|
|
|
6
|
3
|
| HLA matching
Less than 1 locus mismatch
More than 1 locus mismatch |
2
|
N/A
N/A |
|
0
|
0
6 |
3 |
5
|
1
4 |
| GVHD prophylaxis
CSA/MTX
CSA/MMF
CSA
CSA/MMF/MTX
CSA/MMF/MPO
CSA/MPO
FK506/MTX
MPO
None | | | | | | | | | | | | | | | | | | | | 1 | | | | | | | | | | | | 8 | | | | | | GVHD prophylaxis | | 0 | | | | | | | | | | 0 | | | | | | | | | 5 | | | | | | | | | | | | | | | | | | | | | |
| | Type of GVHD | Steroid refractory cGVHD (14) | Steroid refractory aGVHD (12)
Steroid refractory cGVHD (8) | Acute cutaneous GVHD steroid naïve (5) | Steroid refractory aGVHD (19)
Steroid refractory cGVHD (21) | Steroid refractory cGVHD | Steroid naïve cGVHD | Steroid refractory aGVHD (10)
Steroid refractory cGVHD (17) | Steroid refractory aGVHD |
| GVHD by organ involved
Skin
Mucous membrane
GIT
Cytopenia
Eyes
Liver
Lung |
11
14
—
2
1
—
2 |
20
6
10
—
5
13
1 |
5
—
—
—
—
—
— |
32
—
15
12
—
14
— |
50
12
2
—
7
52
— |
26
—
11
—
—
4
— |
12
14
7
—
2
15
— |
23
—
23
—
—
4
— |
|
|
HM: hematologic malignancy; BH: benign hematologic diseases; HLA: human leucocyte antigen; MPO: methyl prednisolone; GIT: gastrointestinal tract; aGVHD: acute graft-versus-host disease; cGVHD: chronic graft-versus-host disease; MTX: methotrexate; N/A: not assessable; CSA: cyclosporin A; MMF: mycophenolate mofetil.
|
